AVISE® APS offers an advanced combination of biomarkers including, anti-phosphatidylserine/prothrombin (PS/PT), to help assess a patient's risk of antiphospholipid syndrome (APS)

AVISE APS – Advanced tests
and methods to aid
in the diagnosis of
antiphospholipid syndrome

Anti-phosphatidylserine/prothrombin (PS/PT) is a recent advancement in assessing a patient’s risk of thrombosis and pregnancy loss associated with APS. In addition, PS/PT has been found to correlate with lupus anticoagulant (LAC) positivity better than other aPL methods regardless of anticoagulant treatment.1

bar graph depicting odds ratios for thrombosis


AVISE APS includes the following markers:

Marker (method) Interpretation
Anti-Phosphatidylserine/Prothrombin (PS/PT) IgM & IgG
(ELISA)
Antibodies to the phosphatidylserine/prothrombin complex are a distinct markers for APS with superior correlation to lupus anticoagulant (LAC).
Anti-Cardiolipin igM, IgG, IgA
(Chemiluminescence)
Antibodies to cardiolipin are present in SLE patients (30-40%) and APS. Prevalence of anti-cardiolipin in APS is high but specificity for APS is lower than other anti-phospholipid antibodies. IgA antibodies to cardiolipin are less prevalent than IgG or IgM but can occur in isolation. Positive results should be confirmed after 12 weeks.
Anti-β2

-Glycoprotein 1 IgM, IgG, IgA
(Chemiluminescence)

Antibodies to Beta 2 Glucoprotein 1 (β2-GP1) show higher specificity than anti-cardiolipin assays. In 3-10% of APS patients, β2-GP1 antibody may be the only positive test. IgA antibodies to β2-GP1 are less prevalent than IgG or IgM but can occur in isolation. Positive results should be confirmed after 12 weeks.


Request more information on AVISE® testing

Pin It on Pinterest

Share This